

1 377 074

(21) Application No. 32780/71 (22) Filed 13 July 1971

(23) Complete Specification filed 6 July 1972

(44) Complete Specification published 11 Dec. 1974

(51) International Classification A61K 23/00

(52) Index at acceptance

A5B 720 727 72Y

(72) Inventors GEOFFREY GREEN,
BRIAN GEORGE OVERELL and
ANTHONY MICHAEL PRATT

(54) PROCESS FOR PREPARING INJECTABLE COMPOSITIONS

(71) We, BEECHAM GROUP LIMITED, a British Company of Beecham House, Great West Road, Brentford, Middlesex, do hereby declare the invention, for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement:—

10 This invention is concerned with a process for preparing finely divided micro-particles of tyrosine having an allergen dispersed therein. The micro-particles prepared according to the invention may be suspended in a physiologically acceptable liquid carrier to produce an injectable composition suitable for use in the desensitisation of individuals who are sensitive to the allergen.

15 In British Patent Specification No. 1,155,036 there is described and claimed a therapeutic composition for injection comprising finely divided solid microparticles of a metabolizable substance having an active drug physically incorporated into the structure of said microparticles, said microparticles being suspended in a physiologically acceptable or non-toxic liquid carrier. The process described in said Specification comprises dissolving the metabolizable substance in hot water or neutral salt solutions, adding 20 the active drug and isolating the precipitate formed on cooling. Compositions such as described in said Specification are especially useful when the active drug is an allergen, since in such cases the injectable composition 25 can be used in desensitisation therapy with less risk of adverse side reactions. For this purpose a particularly useful metabolizable substance is tyrosine, but we have found that with tyrosine, and active allergens, the 30 process described in British Specification No. 1,155,036 is far from satisfactory. Firstly since tyrosine is only soluble in hot water to a very small extent (0.244 g./100 ml. at 75°C), the very large and cumbersome volumes of material make the process difficult. Secondly, with the known process, control

of the size of the precipitated microparticles is very difficult, involving among other things a controlled degree of supercooling. Since the microparticles are for injection, it is clear that the presence of even one large crystal of tyrosine in the micro-fine precipitate is unacceptable, since the hypodermic needle would be blocked during the giving of the injection.

50 This invention is based on the discovery of a process by which these disadvantages of the known process are substantially overcome.

55 According to the present invention there is provided a process for preparing finely divided microparticles of tyrosine having an allergen dispersed therein, which process comprises mixing a solution of tyrosine in a strong aqueous acid with an aqueous or water-miscible solution of the desired allergen and simultaneously or subsequently neutralising the resultant solution, whereby finely-divided microparticles of tyrosine containing the allergen are precipitated; and subsequently separating the said microparticles.

60 Preferably the pH of the reaction medium is not allowed to rise above pH 7 for any substantial length of time during the process of this invention, since the degree of binding of allergen by the tyrosine decreases if precipitation occurs at higher pH's.

65 As used in the Specification "neutralisation" is to be understood as adjustment of pH to a value within the range of 4 to 7.

70 The strong acid which is employed in this process is usually an inorganic acid. Hydrochloric acid is preferred since it is normally present in biological fluids, but nitric and sulphuric acids could be used. Phosphoric acid, although useable, is a much poorer solvent and is therefore not recommended. The molar quantity of acid required varies with its concentration. For example with a concentration range 3.0 to 3.5 N HCl, a quantity of about 0.00924 moles will suffice to dissolve 1g of tyrosine,

[Price 25p]

but at lower concentrations greater amounts are required. Normal trial and error will generally be sufficient to determine the requisite amount of any particular acid.

5 The solution of allergen, which is added to the tyrosine solution may be in an entirely aqueous medium or in an aqueous medium containing one or more water miscible solvents for example, glycerol.

10 The base used to neutralise the solution of tyrosine and allergen is usually sodium hydroxide, for reasons of economy and convenience, but the identity of the base does not appear to be critical. More important than the identity of the base is the necessary to ensure that at no time, or at least for no prolonged time during the neutralisation, does the solution rise appreciably above pH 7. This condition can be met by vigorous stirring of the solution and by the use only of the required amount of base (i.e. avoiding an excess of base over the amount theoretically necessary to neutralise the strong acid.) If desired, various buffering agents can be incorporated in the neutralising base to assist in pH control. We find that the final pH of the neutralised solution should preferably be in the range pH 4 to pH 6.

15 If the pH conditions are met, the bulk, of the micro-fine precipitate of tyrosine containing the allergen will precipitate from the neutralised solution immediately, and is preferably completed by standing for a period, of from a few hours to a day or two. The fineness of the precipitate can be controlled to some extent by varying the rate of neutralisation and the degree of agitation of the solution during neutralisation. Generally, the faster the neutralisation is carried out and the more vigorously the solution is stirred, the finer the precipitate obtained.

20 The allergen solution which is mixed with the tyrosine solution in the present process is prepared by known procedures. Allergenic extracts of whole allergens such as, for example, pollens, house dust, cat fur or dog hair are well known in desensitisation therapy. It should, however, be noted that some allergens are acid-sensitive, and when such allergens are to be subjected to the present process, special care is needed to ensure that the allergen is not subjected to extreme acid conditions. This may be achieved by the method exemplified in Example 4 below, where the solution of allergen and a solution of the neutralising agent are added separately to the acidic solution of tyrosine with rigorous pH control.

25 The product of the present process is a micro-fine precipitate of tyrosine containing the allergen. This may be removed from the solution by centrifugation or filtration, washed e.g. with phenol-saline, and finally resuspended in a liquid physiologically-acceptable carrier such as phenol saline, to

produce an injectable composition suitable for use in desensitisation therapy.

The following Examples illustrate the present invention:—

EXAMPLE 1

DL-Tyrosine (1 g) is dissolved in dilute hydrochloric acid. The molar quantity of acid required varies with its concentration. Within the concentration range 3—3.5 N HCl a quantity of 0.00924 moles of HCl suffices, but at lower concentrations greater amounts are required. An extract of mixed grass pollens, which may be in an entirely aqueous medium, or in a medium containing glycerol or other water-miscible solvents, is then added (e.g. 3.33 ml of an extract containing 60,000 Noon units/ml, which has been prepared by extraction of mixed grass pollens with a mixture of sodium chloride 3000 g, liquefied phenol B.P. 295 ml, distilled water 24.1 and glycerin B.P. 23 l). Before addition to the tyrosine solution, the pollen extract is diluted with sufficient water to give a total volume when added to the tyrosine solution of 10.76 ml. Immediately, afterwards N NaOH (equivalent to the HCl originally used: e.g. 9.24 ml in the example quoted) is run in as rapidly as possible with cooling and with vigorous stirring. The final pH should be on the acid side of neutrality, and preferably within the range of pH 4 to 6. The suspension is preferably allowed to stand for a period of from 1 to 24 hours, and then centrifuged. The precipitate is washed repeatedly with phenol-saline solution, and finally resuspended to a convenient concentration, for instance, 50 mg/ml of tyrosine.

EXAMPLE 2

L-Tyrosine (947.5 g) was dissolved in 3.5N hydrochloric acid (2.5 l), and the solution was sterile filtered. A 20% w/v extract of house dust in Evan's solution was dialysed and concentrated to two-fifteenths of its initial volume, and the concentrate was sterile filtered. 2.4 l of the tyrosine solution was mixed with 3 l of the house dust solution. The combined solutions were vigorously stirred under sterile conditions, and a solution of sodium phosphate in sodium hydroxide ($\text{NaH}_2\text{PO}_4 \cdot 2\text{H}_2\text{O}$ 1.000 g, N NaOH, to 10 l) was run in until a pH of 5.0 was attained. The suspension was allowed to stand for 24 hours, then centrifuged, washed repeatedly in phenol-saline, and finally resuspended in the same medium to a volume of 6 l.

EXAMPLE 3

L-Tyrosine (300 g) was dissolved in 800 ml of 3.5N hydrochloric acid. 800 ml of this sterile filtered solution was mixed with 1000 ml of a sterile 6% extract of mixed grass pollens, which had been extracted with

70

75

80

85

90

95

100

105

110

115

120

125

130

the glycerol medium described in Example 1, and 1500 ml of sterile distilled water. The stirred mixture was treated with sodium phosphate solution as described in Example 2. After standing for 24 hours, the suspension was centrifuged, washed repeatedly with phenol saline, and resuspended in the same medium.

10

EXAMPLE 4

1000 ml of a sterile-filtered 6% extract of mixed grass pollens, prepared in aqueous glycerol medium as described in Example 1, was mixed with 1500 ml of sterile distilled water. The solution was stirred vigorously, and 800 ml of tyrosine solution, prepared as in Example 3, and sodium phosphate solution, prepared as in Example 2, were run in separately under control of a pH-stat so that the pH of the stirred mixture was maintained at 5.0 and did not exceed the limits of pH 4—6. When all the tyrosine solution had been added, the suspension was allowed to stand for 24 hours, centrifuged, washed repeatedly with phenol saline, and finally resuspended in the same medium.

15

WHAT WE CLAIM IS:—

30 1. A process for preparing finely divided micro-particles of tyrosine having an allergen dispersed therein, which process comprises mixing a solution of tyrosine in a strong aqueous acid with an aqueous or water-miscible solution of the desired allergen and simultaneously or subsequently neutralising (as hereinbefore defined) the result-

20

25

ant solution whereby finely-divided micro-particles of tyrosine containing the allergen are precipitated; and subsequently separating the micro-particles.

40

2. A process as claimed in Claim 1 wherein the said strong aqueous acid is hydrochloric acid.

45

3. A process as claimed in either Claim 1 or Claim 2 wherein the solution of tyrosine and allergen is neutralised using sodium hydroxide.

50

4. A process as claimed in any one of the preceding Claims wherein the allergen is present in a solution in aqueous glycerol.

55

5. A process as claimed in any one of Claims 1—4, substantially as described in any one of Examples 1—4.

60

6. A process as claimed in any one of the preceding claims, which process comprises the additional step of resuspending the tyrosine containing the allergen in a liquid physiologically acceptable carrier to produce an injectable composition.

65

7. Micro-particles of tyrosine having an allergen dispersed therein, whenever prepared by a process as claimed in any one of Claims 1—5.

70

8. An injectable composition comprising micro-particles of tyrosine having an allergen dispersed therein, said micro-particles suspended in a liquid physiologically acceptable carrier, whenever prepared by a process as claimed in Claim 6.

RONALD SMITHER,
Chartered Patent Agent,
Agent for the Applicants.

Printed for Her Majesty's Stationery Office by Burgess & Son (Abingdon), Ltd.—1974.
Published at The Patent Office, 25 Southampton Buildings, London, WC2A 1AY
from which copies may be obtained.